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Nucleosome assembly alters the accessibility of the antitumor 
agent duocarmycin B2 to duplex DNA 
Tingting Zoua, Seiichiro Kizakia, Ganesh N. Pandianb, Hiroshi Sugiyamaa,b*  
 
Advancing anti-tumor agents is of significant importance, as 
effective chemotherapy of malignant tumors is one of the great 
challenges of modern medicine[1]. Conventional agents have 
been applied to many cancer therapies, and new anti-tumor 
agents having therapeutic potential are being discovered. 
Duocarmycin,  first reported in 1988 [2][3] and their analogues 
have been beneficial in treating many types of tumor 
disease[1][4]via covalent interaction with DNA minor groove 
adenine N3 alkylation site[5][6]. However, in eukaryotic cells, the 
assembly of DNA and histone proteins into nucleosomes (the 
basic repeating subunits of chromatin) packs over two meters of 
DNA into the confines of the nucleus[7]. In such a highly compact 
structure, whether antitumor agents exhibit similar or distinct 
accessibility to duplex DNA as in the naked condition is yet to be 
clarified. 
A report about the accessible regions of nucleosome core 
particles (NCPs) to minor-groove-binding pyrrole-imidazole 
polyamides (PIPs) showed that PIPs fail to bind NCPs only at 
sites that are blocked by interactions with the histone octamer[8]. 
NCPs were also shown to be fully accessible to some minor-
groove-alkylating agents, and both the selectivity and efficiency 
of DNA alkylation were suggested to be unaffected by NCP 
packaging[9]. Furthermore, the base pair unstacking arising from 
DNA stretch induce extreme minor groove kinking near the 
nucleosome center, which in turn generate a hot spot for 
intercalation facilitating the alkylation by a novel anticancer 
compound[10].  
   However, in the actual chromatin condition, each nucleosome 
encompass not only nucleosome ‘core’, but also linker DNA, and 
in most instances, a linker histone[11]. As the essential 
composition of nucleosome, linker DNA provide a binding region 
for linker histone and then regulate epigenetic transcription[12]. 
Cisplatin and analogues were demonstrated that the preferred 
site of DNA binding was in the linker region of the nucleosome[13]. 
Some researchers adopted DNA fragment from the Xenopus 
Zaeuis 5 S rRNA gene for nucleosome reconstitution. The 
results exhibited that marked inhibition of the DNA cleavage 
induced by bleomycin (5 fold) and neocarzinostatin (2.4 fold) in 
the central region of nucleosomal DNA. Also in melphalan, about 
2 fold inhibition in alkylation at adenine N-3 throughout the 
nucleosome was shown[14][15]. 
Taken together, the previous reports suggest the existence of 
undiscovered nucleosome features that can be harnessed in 
advancing the cancer drug discovery. Accordingly, 382 bp DNA 
containing Widom 601 nucleosome positioning sequence and 
duocarmycin B2 were adopted for the nucleosome reconstitution 
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Abstract: To evaluate the reactivity of antitumor agents in a 
nucleosome architecture, we conducted in vitro studies to 
assess the alkylation level of duocarmycin B2 on 
nucleosomes with core and linker DNA using sequencing 
gel electrophoresis. Our results suggested that the 
alkylating efficiencies of duocarmycin B2 were significantly 
decreased in core DNA and increased at the histone-free 
linker DNA sites when compared with naked DNA condition. 
Our finding that nucleosome assembly alters the 
accessibility of duocarmycin B2 to duplex DNA could 
advance their design as antitumor agents. 
Figure 1.  (A) Preparation of mono-nucleosome; (B) Mechanism of 
duocarmycin B2 alkylating DNA 














and evaluation, to verify the influence of nucleosome assembly 
with linker part on the accessibility of small molecular agents into 
duplex DNA.  
   To construct the nucleosome structure, we used Texas red 
labeled 382 bp DNA containing 146 bp nucleosome-positioning 
601 sequence[16] flanked by two DNA arms of different lengths, 
125 and 111 bp, respectively (Figure 1A, Figure 2). 
Subsequently, we amplified DNA through PCR from pGEM3Z-
601 using the following primers: forward, 5′-Texas Red 
TAATACGACTCACTATAGG-3′, and reverse, 5′-
ATTTAGGTGACACTATAGAATAC-3′[17]. After the reaction, the 
amplified DNA was purified using the GenElute PCR Clean-Up 
Kit (Sigma-Aldrich, St. Louis, MO, USA),  The purified DNA was 
then used for nucleosome reconstitution with histone octamer 
(Epicypher, NC, USA) by standard salt gradient method[18][19]. 
The reconstitution efficiency was confirmed by gel mobility shift 
assay (6% Native PAGE, 100V, 1h). 
Duocarmycin B2 at various concentrations with 6.25 mM 
sodium phosphate buffer (pH 7.0) alkylated the 5’-Texas Red 
labeled 382 bp free-DNA or nucleosomes at room temperature 
for 18 h. After incubation, the reaction mixture was quenched by 
addition of calf thymus DNA followed by heat treatment at 95℃ 
for 10 min. The alkylating mechanism of duocarmycin B2 was 
showed in Figure 1B.  The solution was concentrated using 
vacuum centrifugation. The pellet was re-dissolved in 7 µL of 
loading dye, heated at 95℃ for 25 min, and then immediately 
cooled down to 0℃. A 0.8 µL aliquot was subjected to 
electrophoresis on a 6% denaturing polyacrylamide gel by using 
a Hitachi DNA sequencer[20]. The results were analyzed and 
shown with FRAGLYS version 2 in SSCP calculation mode. 
The reconstituted nucleosomes confirmed by gel mobility shift 
assay (Figure S1) were directly used for alkylating reaction. After 
incubation at room temperature for 18 h, gel shift was also used 
for confirming the nucleosome condition, in consistent with 
previous report[9], the result 	 (Figure S2) indicated that 
nucleosome dissociation was not caused by the treatment with 
agents, nucleosomes incubated at room temperature showed 
similar stability as incubated at 4℃ for 18 hours. Because 
prolonging the cleaving time from 10 min to 50 min did not yield 
significant difference (Figure S3), heating at 95℃ for 10 min was 
adopted in the subsequent investigations.  
Varying concentrations of duocarmycin B2 were tested in the 
presence of free-DNA or nucleosome in 20 nM (Figure 3). In 
accordance with a previous report [9], no unexpected alkylating 
sites were observed in either free DNA or nucleosomes. Both 
DNA and nucleosomes were alkylated to a higher degree with 
increasing concentrations of duocarmycin B2. Figure 2 indicates 
that, in the core DNA, all three alkylating sites located in the 
minor groove inward region, which is consistent with previous 
research. While evaluating the alkylating efficiency, while was 
we observed notable alkylating efficiency differences between 
nucleosome and free DNA samples. In the core DNA region, 
three alkylating sites were found which all showed an obvious 
decreasing alkylating efficiency for nucleosomes compared with 
free DNA, site 2 even exhibited a decrease in efficiency more 
than 3 fold (from 21.5% to 6.3%) in the presence of 0.5 µM 
duocarmycin B2 (Figures 3 and 4). However, the first site, which 
includes three possible alkylating adenines (Figure 2), 
sometimes shows fluctuating efficiency changes for predictable 
better agent accessibility. 
Figure 3.  Thermally induced strand cleavage (10 min, 95℃) of 382 bp 
DNA and nucleosome with different concentration of duocarmycin B2.	  
lanes 1-4, free DNA (20 nM) + duocarmycin B2 (0.1 µM, 0.25 µM,0.5 µM, 
respectively) ; lanes 5-8, nucleosome (20 nM) + duocarmycin B2 (0.1 µM, 
0.25 µM,0.5 µM, respectively). 
Figure 2. The sequence of  382 bp DNA and alkylating sites in core and linker DNA fragment. 





 In contrast with the decreasing alkylating efficacy observed at 
core sites, the efficiency of alkylating sites in the nucleosome 
linker DNA region was significantly increased when compared 
with that observed in the free DNA (Figure 3, Figure 4). 
Alkylating sites 5 on linker DNA region, which possesses a 
relatively higher reaction activity for two potential alkylating 
adenines, showed the most obvious alkylating band and 
efficiency increased from 9.7% to 15.0% in nucleosomal DNA. 
These results also suggest that, in the nucleosome structure, the 
linker DNA region shows similar or higher reactivity than the 
core DNA region. While in the naked DNA condition, lower 
reactivity in DNA linker region could be observed.  
We also attempted to confirm these results using different 	
concentrations of free DNA and nucleosome in the presence of 
0.5 µM duocarmycin B2, and similar tendencies were observed 
(Figure S4). These results indicated that the accessibility of 
duocarmycin B2 to duplex DNA is altered in the presence of 
nucleosome assembly and the agent preferentially alkylates the 
naked DNA part (linker region) rather than the DNA that is 
packaged with histone proteins.  
In conclusion, this present in vitro study was conducted to 
elucidate the mechanistic information regarding the accessibility 
of duocarmycin B2 to duplex DNA in nucleosomes containing a 
linker DNA region. Compared with free DNA, in the presence of 
nucleosome structure, duocarmycin B2 showed a significantly 
decreased efficiency in accessing the nucleosome core DNA, 
while exhibiting an increased efficiency in accessing the linker 
DNA region. This finding also suggested that although the 
efficiency of alkylating agents enters into nucleosome core 
region showed decreased binding, the targeting capability is still 
retained, and even higher in linker DNA region, while might be 
considered when designing drugs for targeting key promoter 
region.  
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Figure 4. Alkylating efficacy of duocarmycin B2 in 0.5 µM, with free 
DNA or nucleosome in 20 nM. The data are mean ± SD of repeated 
experiments  (n=3). 











Nucleosome assembly influence:  
In vitro studies aimed at evaluating 
the alkylation level of duocarmycin B2 
on nucleosomes with core and linker 
DNA were conducted using 
sequencing gel electrophoresis. Our 
results suggested that in nucleosome 
structure, the alkylating efficiencies of 
duocarmycin B2 were significantly 
decreased in core DNA and increased 
at the histone-free linker DNA sites 
compared with naked DNA condition.  
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Figure S1. Nucleosome reconstitution efficiency confirmation, native gel electrophoresis of Texas red 
labeled 382 bp DNA and reconstituted nucleosomes (DNA: histone octamer in 2:3 molar ratio). Lane 1, 






















Figure S2. Nucleosome stability confirmation, non-denaturing gel electrophoresis of 5’ end-Texas red 
labeled 601 DNA and reconstituted nucleosomes (DNA : histone octamer in 2:3). Lane 1, control free 
DNA; lane 2, reconstituted 601 nucleosome; lanes 3-8,  room temperature, 18 h, DNA or nucleosome in 
20 nM, 3: DNA with duocarmycin (0.1 μM), 4: nucleosome control, 5-6: nucleosome with duocarmycin (0.1 
μM), 7-8: nucleosome with duocarmycin (0.5 μM); lanes 9-14, 4℃, 18 h, 9: DNA with duocarmycin (0.1 
μM), 10: nucleosome control, 11-12: nucleosome with duocarmycin (0.1 μM), 13-14: nucleosome with 






























Figure S3. Thermally induced strand cleavage of 382 bp DNA and nucleosome with different heating 
time. Lanes 1-3, free DNA (30 nM ) + duocarmycin B2 (0.5 μM), heating in 95℃ (10 min, 25 min, 50 
min, respectively) ; lane 4-6, nucleosome (30 nM ) + duocarmycin B2 (0.5 μM), heating in 95℃ (10 































Figure S4. Thermally induced strand cleavage (10 min, 95℃). lane 1, control free DNA; lanes 
2-4, duocarmycin B2 (0.5 μM) + free DNA (10 nM, 20 nM  and 30 nM respectively); lane 5, 
control nucleosome; lanes 6-8, duocarmycin B2 (0.5  μM) + nucleosome (10 nM, 20 nM  
and 30 nM, respectively). 
